KPV is the Lys-Pro-Val tripeptide studied in inflammation research, including experimental colitis. The cited mechanistic and preclinical findings do not establish it as a treatment for human inflammatory bowel disease.
What the research shows
A 2008 study examined PepT1 transport and inflammation in cells and mice. A 2016 study included mouse experiments concerning colitis and inflammation-associated cancer. Human tissue observations within research do not make it a KPV treatment trial in patients. [1] [2] [3]
Related substances appeared on the FDA’s 2026 compounding agenda; this is not product approval. [3]
Distinguishing substances and products
KPV is not BPC-157. A shared gastrointestinal topic does not establish interchangeability or equal effects. Findings from mixtures also should not automatically be attributed to a single component.
Reading a specific brand’s label
Start with the exact substance and product name, then match the label to the manufacturer’s documents. This article does not establish Thai registration or current availability for an unspecified product.
Frequently asked questions
Are KPV and BPC-157 the same substance?
No. They require substance-specific evidence.
Does human tissue research count as a patient-treatment trial?
Not by itself. The study must actually assess treatment and clinical outcomes in patients.
What information helps identify a specific product?
The brand, product name, full label and matching manufacturer documents. Evidence about the substance alone does not establish a product’s identity, registration or quality.
Related information
For general questions about names or label details, contact LINE: @musclestationth
Sources and review date
Sources checked: 11 September 2026. This page explains selected primary sources; it is not a systematic review of every study.